dc.rights.license | open | en_US |
dc.contributor.author | BONI, Simon P | |
dc.contributor.author | TENET, Vanessa | |
dc.contributor.author | HORO, Apollinaire | |
dc.contributor.author | HEIDEMAN, Danielle A M | |
dc.contributor.author | BLEEKER, Maaike C G | |
dc.contributor.author | TANON, Aristophane | |
dc.contributor.author | MIAN, Boston | |
dc.contributor.author | MOHENOU, Isidore D | |
hal.structure.identifier | Bordeaux population health [BPH] | |
hal.structure.identifier | Global Health in the Global South [GHiGS] | |
dc.contributor.author | EKOUEVI, Didier Koumavi | |
dc.contributor.author | GHEIT, Tarik | |
dc.contributor.author | DIDI-KOUKO COULIBALY, Judith | |
dc.contributor.author | TCHOUNGA, Boris K | |
dc.contributor.author | ADOUBI, Innocent | |
dc.contributor.author | CLIFFORD, Gary M | |
hal.structure.identifier | Bordeaux population health [BPH] | |
hal.structure.identifier | Global Health in the Global South [GHiGS] | |
dc.contributor.author | JAQUET, Antoine | |
dc.date.accessioned | 2024-01-10T09:00:57Z | |
dc.date.available | 2024-01-10T09:00:57Z | |
dc.date.issued | 2023-11-09 | |
dc.identifier.issn | 1097-0215 | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/186998 | |
dc.description.abstractEn | As human papillomavirus (HPV) immunisation and HPV-based cervical cancer (CC) screening programmes expand across sub-Saharan Africa, we investigated the potential impact of human immunodeficiency virus (HIV) status on high-risk (HR)-HPV distribution among women with CC in Cote d'Ivoire. From July 2018 to June 2020, paraffin-embedded CC specimens diagnosed in Abidjan, Cote d'Ivoire were systematically collected and tested for HR-HPV DNA. Type-specific HR-HPV prevalence was compared according to HIV status. Of the 170 CC specimens analysed (median age 52 years, interquartile range: [43.0-60.0]), 43 (25.3%) were from women living with HIV (WLHIV) with a median CD4 count of 526 [373-833] cells/mm(3) and 86% were on antiretroviral therapy (ART). The overall HR-HPV prevalence was 89.4% [95% CI: 84.7-94.1]. All were single HR-HPV infections with no differences according to HIV status (P = .8). Among HR-HPV-positive CC specimens, the most prevalent HR-HPV types were HPV16 (57.2%), HPV18 (19.7%), HPV45 (8.6%) and HPV35 (4.6%), with no significant differences according to HIV status. Altogether, infection with HPV16/18 accounted for 71.1% [95% CI: 55.9-86.2] of CC cases in WLHIV vs 78.9% [95% CI: 71.3-86.5] in women without HIV (P = .3). The study confirms the major role of HPV16/18 in CC in Cote d'Ivoire and should support a regional scale-up of HPV16/18 vaccination programmes regardless of HIV status. However, vaccines targeting additional HR-HPV types, including HPV45 and HPV35, could further decrease future CC incidence in Cote d'Ivoire, both for WLHIV and women without HIV. | |
dc.language.iso | EN | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.subject.en | cervical cancer | |
dc.subject.en | Côte d'Ivoire | |
dc.subject.en | high-risk human papillomavirus | |
dc.subject.en | human immunodeficiency virus | |
dc.title.en | High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Cote d'Ivoire, 2018 to 2020 | |
dc.title.alternative | Int J Cancer | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1002/ijc.34774 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 37942579 | en_US |
bordeaux.journal | International Journal of Cancer | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | GHIGS_BPH | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
bordeaux.identifier.funderID | Eunice Kennedy Shriver National Institute of Child Health and Human Development | en_US |
bordeaux.identifier.funderID | National Cancer Institute | en_US |
bordeaux.identifier.funderID | Fogarty International Center | en_US |
bordeaux.identifier.funderID | National Heart, Lung, and Blood Institute | en_US |
bordeaux.identifier.funderID | National Institute on Drug Abuse | en_US |
bordeaux.identifier.funderID | National Institute on Alcohol Abuse and Alcoholism | en_US |
bordeaux.identifier.funderID | National Institute of Diabetes and Digestive and Kidney Diseases | en_US |
bordeaux.identifier.funderID | U.S. National Library of Medicine | en_US |
bordeaux.identifier.funderID | Institut de Recherche pour le Développement | en_US |
hal.identifier | hal-04384266 | |
hal.version | 1 | |
hal.date.transferred | 2024-01-10T09:01:01Z | |
hal.popular | non | en_US |
hal.audience | Internationale | en_US |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International%20Journal%20of%20Cancer&rft.date=2023-11-09&rft.eissn=1097-0215&rft.issn=1097-0215&rft.au=BONI,%20Simon%20P&TENET,%20Vanessa&HORO,%20Apollinaire&HEIDEMAN,%20Danielle%20A%20M&BLEEKER,%20Maaike%20C%20G&rft.genre=article | |